Ola Weiland

14.6k total citations · 2 hit papers
254 papers, 9.2k citations indexed

About

Ola Weiland is a scholar working on Hepatology, Epidemiology and Rheumatology. According to data from OpenAlex, Ola Weiland has authored 254 papers receiving a total of 9.2k indexed citations (citations by other indexed papers that have themselves been cited), including 214 papers in Hepatology, 194 papers in Epidemiology and 38 papers in Rheumatology. Recurrent topics in Ola Weiland's work include Hepatitis C virus research (189 papers), Hepatitis B Virus Studies (134 papers) and Liver Disease Diagnosis and Treatment (127 papers). Ola Weiland is often cited by papers focused on Hepatitis C virus research (189 papers), Hepatitis B Virus Studies (134 papers) and Liver Disease Diagnosis and Treatment (127 papers). Ola Weiland collaborates with scholars based in Sweden, United States and Germany. Ola Weiland's co-authors include Robert Schvarcz, Olle Reichard, Gunnar Norkrans, Aril Frydén, Lars Mattsson, Anders Sönnerborg, Stefan Zeuzem, Zhibing Yun, Rune Wejstål and Hans Glaumann and has published in prestigious journals such as New England Journal of Medicine, The Lancet and The Journal of Immunology.

In The Last Decade

Ola Weiland

249 papers receiving 8.8k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Treatment of HCV with ABT-450/r–Ombitasvir and Dasabuvir with Ribavirin

2014 686 citations Eoin Coakley, Ola Weiland et al. profile →
Sofosbuvir and Ribavirin in HCV Genotypes 2 and 3

2014 592 citations Stefan Zeuzem, Geoffrey Dusheiko et al. profile →

Peers

Countries citing papers authored by Ola Weiland

Since Specialization

Citations

This map shows the geographic impact of Ola Weiland's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ola Weiland with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ola Weiland more than expected).

Fields of papers citing papers by Ola Weiland

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ola Weiland. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ola Weiland. The network helps show where Ola Weiland may publish in the future.

Co-authorship network of co-authors of Ola Weiland

This figure shows the co-authorship network connecting the top 25 collaborators of Ola Weiland. A scholar is included among the top collaborators of Ola Weiland based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ola Weiland. Ola Weiland is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Value appropriation in hepatitis C 2021 ·The European Journal of Health Economics ·Peter Lindgren, Sofia Löfvendahl, (unknown), Ola Weiland, Bengt Jönsson	2
2	Mutations Identified in the Hepatitis C Virus (HCV) Polymerase of Patients with Chronic HCV Treated with Ribavirin Cause Resistance and Affect Viral Replication Fidelity 2020 ·Antimicrobial Agents and Chemotherapy ·(unknown), Ulrik Fahnøe, Andrea Galli, Santseharay Ramírez, Ola Weiland, Thomas Benfield, Jens Bukh	8
3	Epidemiology and causes of death in a Swedish cohort of patients with autoimmune hepatitis 2017 ·Scandinavian Journal of Gastroenterology ·(unknown), Hanns–Ulrich Marschall, Annika Bergquist, Fredrik Rorsman, Ola Weiland, Stergios Kechagias, Nils Nyhlin, Hans Verbaan, Emma Nilsson, Mårten Werner	40
4	Daclatasvir plus sofosbuvir, with or without ribavirin, achieved high sustained virological response rates in patients with HCV infection and advanced liver disease in a real-world cohort 2016 ·Gut ·Tania M. Welzel, Jörg Petersen, Kerstin Herzer, Péter Ferenci, Michael Gschwantler, Heiner Wedemeyer, Thomas Berg, Ulrich Spengler, Ola Weiland, Marc van der Valk, Jürgen K. Rockstroh, Markus Peck‐Radosavljevic, Yue Zhao, María Jesús Jiménez‐Expósito, Stefan Zeuzem	133
5	Diabetes and Cirrhosis Are Risk Factors for Hepatocellular Carcinoma After Successful Treatment of Chronic Hepatitis C 2016 ·Clinical Infectious Diseases ·Magnus Hedenstierna, (unknown), Ola Weiland, Soo Aleman	34
6	SVR12 Rate of 98.6% in 992 HCV Genotype 1b-Infected Patients Treated with ABT-450/r/Ombitasvir and Dasabuvir With or Without Ribavirin 2014 ·Hepatology ·Massimo Colombo, Ola Weiland, Daniel E. Cohen, Jean‐François Dufour, Hendrik Reynaert, M. Diago, Erica Villa, Adrian Streinu‐Cercel, Wangang Xie, Tolga Baykal, Jeffrey Enejosa, Eoin Coakley, Roger Trinh, Thomas Podsadecki	2
7	506 UNDETECTABLE HCV-RNA IN TELAPREVIR-TREATED PATIENTS: LOW CONCORDANCE BETWEEN TWO HIGHLY SENSITIVE REAL-TIME PCR ASSAYS 2013 ·Journal of Hepatology ·Johannes Vermehren, Alessio Aghemo, Kai‐Henrik Peiffer, S. Süsser, Roberta D’Ambrosio, D. Perner, Lynn H. Gerber, R. Soffredini, Ola Weiland, Stefan Zeuzem, Massimo Colombo, C. Sarrazin	2
8	497 SPONTANEOUS CLEARANCE OR CHRONIC EVOLUTION OF HCV IN HIV/HCV CO-INFECTED PATIENTS – INFLUENCE OF THE IL28B GENOTYPE 2013 ·Journal of Hepatology ·(unknown), (unknown), Karolin Falconer, Anders Sönnerborg, Ola Weiland	1
9	Concentration‐guided ribavirin dosing with darbepoetin support and peg‐IFN alfa‐2a for treatment of hepatitis C recurrence after liver transplantation 2012 ·Journal of Viral Hepatitis ·(unknown), Henrik Gjertsen, Annika Wernerson, Ola Weiland	7
10	Elevated Numbers of FcγRIIIA+ (CD16+) Effector CD8 T Cells with NK Cell-Like Function in Chronic Hepatitis C Virus Infection 2008 ·The Journal of Immunology ·Niklas K. Björkström, Veronica D. Gonzalez, Karl‐Johan Malmberg, Karolin Falconer, Annette Alaeus, Greg Nowak, Carl Jorns, Bo‐Göran Ericzon, Ola Weiland, Johan K. Sandberg, Hans‐Gustaf Ljunggren	56
11	Efficacy of 6 months treatment with PEG-interferon alpha-2b plus ribavirin (P/R) in patients infected with hepatitis C with genotype 1 of low viral load (G1LVL) 2005 ·Journal of Hepatology ·Stefan Zeuzem, Yves Horsmans, Rafael Esteban, Péter Ferenci, Jan Šperl, J Cianciara, E Ibrányi, Ola Weiland, Stephanie Noviello, Clifford A. Brass	5
12	Histological findings, genotype distribution and percentage of patients fulfilling the treatment criteria among patients with chronic hepatitis C virus infection in a single Swedish centre 2004 ·Scandinavian Journal of Gastroenterology ·A. Gerson Hollander, Hans Glaumann, Ola Weiland	6
13	The GB Virus C/Hepatitis G Virus Replicates in Hepatocytes without Causing Liver Disease in Healthy Blood Donors 2000 ·The Journal of Infectious Diseases ·(unknown), Matti Sällberg, (unknown), Göran Andersson, (unknown), Hans Glaumann, Ola Weiland	14
14	GBV-C/HGV infection in hepatitis C virus-infected deferred Swedish blood donors 1998 ·Journal of Medical Virology ·Steven Shev, Per Björkman, Gunnar Norkrans, Ulla Foberg, Aril Frydén, Gudrun Lindh, Annika Lindholm, Ola Weiland, Anders Widell	22
15	Interferon‐α Treatment Induces Delayed CD4 Proliferative Responses to the Hepatitis C Virus Nonstructural Protein 3 Regardless of the Outcome of Therapy 1997 ·The Journal of Infectious Diseases ·Zhu‐Xu Zhang, David R. Milich, Darrell L. Peterson, Ashley J. Birkett, Robert Schvarcz, Ola Weiland, Matti Sällberg	39
16	Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed to achieve sustained response to interferon alone: Swedish experience. 1995 ·PubMed ·Robert Schvarcz, Yukio Ando, Anders Sönnerborg, Ola Weiland	64
17	RESULTS OF A PLACEBO-CONTROLLED STUDY OF RIBAVIRIN IN PATIENTS WITH CHRONIC HEPATITIS-C 1994 ·UCL Discovery (University College London) ·Geoffrey Dusheiko, Ola Weiland, (unknown), Olle Reichard, (unknown), (unknown), Aril Frydén, Hendrik W. Reesink, (unknown), Gunnar Norkrans, (unknown), (unknown), (unknown), Paul Telfer, (unknown), (unknown), (unknown)	6
18	Second‐Generation Hepatitis C Elisa Antibody Tests Confirmed by the Four‐Antigen Recombinant Immunoblot Assay Correlate Well with Hepatitis C Viremia and Chronic Liver Disease in Swedish Blood Donors 1993 ·Vox Sanguinis ·Steven Shev, Ulla Foberg, Aril Frydén, Svante Hermodsson, Gudrun Lindh, A Lindholm, (unknown), Madeleine von Sydow, Ola Weiland, (unknown), (unknown)	19
19	Non-A, non-B Hepatitis after Open-heart Surgery in Stockholm: Declining Incidence after Introduction of Restrictions for Blood Donations due to the Human Immunodeficiency Virus 1988 ·Scandinavian Journal of Infectious Diseases ·Lars Mattsson, Bengt Åberg, Ola Weiland, (unknown), (unknown)	21
20	EBV specific killer T cells and serologic responses after onset of infectious mononucleosis. 1978 ·Munich Personal RePEc Archive (Ludwig Maximilian University of Munich) ·Erik Svedmyr, Mikael Jondal, Werner Henle, Ola Weiland, Lars Rombo, George Klein	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact